Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer.

ABSTRACT:

Introduction

The introduction of targeted drugs has had a significant impact on the approach to assessing tumour response. These drugs often induce a rapid cytostatic effect associated with a less pronounced and slower tumoural volume reduction, thereby impairing the correlation between the absence of tumour shrinkage and the patient's unlikelihood of benefit. The aim of the study was to assess the predictive value of early metabolic response (mR) evaluation after one cycle, and its interlesional heterogeneity to a later metabolic and morphological response assessment performed after three cycles in metastatic colorectal cancer (mCRC) patients treated with combined sorafenib and capecitabine.

Methods

This substudy was performed within the framework of a wider prospective mul

SUBMITTER: Woff E 

PROVIDER: S-EPMC4969337 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature